ARDX vs AZN

Ardelyx (ARDX) exhibits a Piotroski F-Score of 4/9, indicating weak financial health and limited operational stability, with no Altman Z-Score available to assess bankruptcy risk. The company trades at a forward P/E of 11.08 and a price/sales ratio of 3.48, suggesting modest valuation relative to peers, though profitability remains negative with a -15.12% profit margin and negative ROE. Despite a 7.8% YoY revenue growth and improving earnings surprise trends, insider selling activity over the past six months—totaling $1.35M in sales—raises governance concerns. Analysts maintain a strong_buy consensus with a $16.10 target, implying significant upside, but this is tempered by high volatility and lack of dividend yield.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.